SB

Srikanth Banarji Myneni

Active Director Director DIN 11305883
DIN 11305883 First appointment Sep 2025 Primary industry Biotechnology
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Srikanth Banarji Myneni

Data last updated:

Srikanth Banarji Myneni is a Director at Safecell Biopharma Private Limited (since 2025). The company operates in Biotechnology.

DIN 11305883
Primary Designation Director
Industry Biotechnology
First Appointment 18 Sep 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Safecell Biopharma Private Limited U71200TS2025PTC204208
Director18 Sep 20252025Active

Board colleagues of Srikanth Banarji Myneni

NameDINCompanyDesignation
Varaprasad V Yarlagadda11305882Safecell Biopharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Safecell Biopharma Private Limited
Premium access

Shareholding and investment profile for Srikanth Banarji Myneni

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Srikanth Banarji Myneni

Srikanth Banarji Myneni currently holds 1 directorship: Safecell Biopharma Private Limited (Director, since 18 Sep 2025).

Srikanth Banarji Myneni was first appointed on 18 Sep 2025 as Director at Safecell Biopharma Private Limited.

The current boards of Srikanth Banarji Myneni's companies include Varaprasad V Yarlagadda (Safecell Biopharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available